Asset Details
Do you wish to reserve the book?
Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy
Do you wish to request the book?
Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy
2023
Overview
Purpose
To investigate the effect of systemic therapy on health-related quality of life (HRQoL) in patients with advanced esophagogastric cancer in daily clinical practice. This study assessed the HRQoL of patients with esophagogastric cancer during first-line systemic therapy, at disease progression, and after progression in a real-world context.
Methods
Patients with advanced esophagogastric cancer (2014–2021) receiving first-line systemic therapy registered in the Prospective Observational Cohort Study of Oesophageal-gastric cancer (POCOP) were included (
n
= 335). HRQoL was measured with the EORTC QLQ-C30 and QLQ-OG25. Outcomes of mixed-effects models were presented as adjusted mean changes.
Results
Results of the mixed-effect models showed the largest significant improvements during systemic therapy for odynophagia (− 18.9,
p
< 0.001), anxiety (− 18.7,
p
< 0.001), and dysphagia (− 13.8,
p
< 0.001) compared to baseline. After progression, global health status (− 6.3,
p
= 0.002) and cognitive (− 6.2,
p
= 0.001) and social functioning (− 9.7,
p
< 0.001) significantly worsened. At and after progression, physical (− 9.0,
p
< 0.001 and − 8.8,
p
< 0.001) and role functioning (− 15.2,
p
= 0.003 and − 14.7,
p
< 0.001) worsened, respectively. Trouble with taste worsened during systemic therapy (11.5,
p
< 0.001), at progression (12.0,
p
= 0.004), and after progression (15.3,
p
< 0.001).
Conclusion
In general, HRQoL outcomes in patients with advanced esophagogastric cancer improved during first-line therapy. Deterioration in outcomes was mainly observed at and after progression.
Implications for cancer survivors
Identification of HRQoL aspects is important in shared decision-making and to inform patients on the impact of systemic therapy on their HRQoL.
